PARP Inhibitors as a New Therapeutic Option in Metastatic Prostate Cancer: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/32367009/
On May 15th is possible that the first PARP inhibitor will be approved by FDA for metastatic prostate cancer. The name of this drug is Rucaparib, developed by Clovis Oncology https://clovisoncology.com/pipeline/rucaparib/
This drug is currently sold under the brand Rubraca, for treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy https://www.rubraca.com
It is encouraging to see new immunotherapy options becoming available to prostate cancer patients as previously, Provenge was the only immunotherapy available. The caveat is that only men with DNA repair mutations or, for other immunotherapy meds like checkpoint inhibitors, PD-L1, PD-L2 or MSI mutations need to be present. I am seeing more and more doctors testing for both germline and somatic mutations in their prostate cancer patients. As the study you posted indicates, DNA repair mutations (BRCA1, BRCA2, ATM) make the cancer vulnerable to both PARP inhibitors and platinum-based chemotherapy. Thanks for posting.
Indeed, the drug was approved:
Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. More Information. May 15, 2020
https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate&source=gmail&ust=1589680886080000&usg=AFQjCNE8MatdMAl6ymMHokFHQlMH4BSzC A"> https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
This is probably the first of the wave of PARP inhibitors to be approved for prostate cancer. At least one more will probably be approved this year.
It is on my list, but drug seems expensive as it won't be covered by insurance:
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status PMC6966531
